SiBone (SIBN) Competitors $18.46 +0.03 (+0.16%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SIBN vs. LIVN, WRBY, NVCR, LMAT, EYE, ENOV, CNMD, AORT, CDRE, and TNDMShould you be buying SiBone stock or one of its competitors? The main competitors of SiBone include LivaNova (LIVN), Warby Parker (WRBY), NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Artivion (AORT), Cadre (CDRE), and Tandem Diabetes Care (TNDM). These companies are all part of the "medical equipment" industry. SiBone vs. Its Competitors LivaNova Warby Parker NovoCure LeMaitre Vascular National Vision Enovis CONMED Artivion Cadre Tandem Diabetes Care LivaNova (NASDAQ:LIVN) and SiBone (NASDAQ:SIBN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership. Do analysts rate LIVN or SIBN? LivaNova presently has a consensus target price of $59.29, indicating a potential upside of 28.52%. SiBone has a consensus target price of $22.50, indicating a potential upside of 21.89%. Given LivaNova's higher probable upside, equities analysts plainly believe LivaNova is more favorable than SiBone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LivaNova 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00SiBone 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, LIVN or SIBN? LivaNova has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, SiBone has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Is LIVN or SIBN more profitable? SiBone has a net margin of -15.03% compared to LivaNova's net margin of -17.41%. LivaNova's return on equity of 13.67% beat SiBone's return on equity.Company Net Margins Return on Equity Return on Assets LivaNova-17.41% 13.67% 6.68% SiBone -15.03%-16.00%-11.69% Does the media favor LIVN or SIBN? In the previous week, LivaNova had 1 more articles in the media than SiBone. MarketBeat recorded 2 mentions for LivaNova and 1 mentions for SiBone. SiBone's average media sentiment score of 1.89 beat LivaNova's score of 1.76 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has stronger valuation and earnings, LIVN or SIBN? LivaNova has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLivaNova$1.25B2.01$63.23M-$4.09-11.28SiBone$167.18M4.71-$30.91M-$0.64-28.84 Do institutionals & insiders have more ownership in LIVN or SIBN? 97.6% of LivaNova shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 0.3% of LivaNova shares are owned by company insiders. Comparatively, 4.0% of SiBone shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryLivaNova beats SiBone on 9 of the 16 factors compared between the two stocks. Get SiBone News Delivered to You Automatically Sign up to receive the latest news and ratings for SIBN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SIBN vs. The Competition Export to ExcelMetricSiBoneMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$787.09M$6.86B$5.54B$9.05BDividend YieldN/A1.21%5.24%4.03%P/E Ratio-28.8426.1527.4320.23Price / Sales4.7199.70420.79118.64Price / CashN/A21.0936.8958.07Price / Book4.644.748.045.67Net Income-$30.91M$173.18M$3.18B$249.13M7 Day Performance0.16%1.33%2.88%3.28%1 Month Performance-3.15%0.16%3.69%5.56%1 Year Performance42.11%23.71%36.15%21.12% SiBone Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SIBNSiBone4.1687 of 5 stars$18.46+0.2%$22.50+21.9%+41.6%$787.09M$167.18M-28.84350Positive NewsLIVNLivaNova3.2426 of 5 stars$45.02-1.6%$59.29+31.7%-12.6%$2.49B$1.25B-11.012,900News CoverageWRBYWarby Parker2.2291 of 5 stars$21.94+0.2%$22.88+4.3%+37.1%$2.29B$771.32M-182.833,780NVCRNovoCure3.6878 of 5 stars$17.80-1.1%$32.83+84.5%+4.9%$2.01B$605.22M-11.791,488LMATLeMaitre Vascular2.7173 of 5 stars$83.05+0.6%$97.83+17.8%+3.8%$1.87B$219.86M41.94490Positive NewsEYENational Vision2.6546 of 5 stars$23.01-0.7%$18.67-18.9%+92.2%$1.83B$1.82B-69.7313,411Positive NewsENOVEnovis3.549 of 5 stars$31.36-1.3%$58.00+84.9%-24.3%$1.82B$2.11B-2.257,367Positive NewsCNMDCONMED4.6558 of 5 stars$52.10-0.1%$62.20+19.4%-19.5%$1.61B$1.31B13.713,900Positive NewsAORTArtivion2.4992 of 5 stars$31.17-0.1%$32.00+2.7%+18.8%$1.33B$388.54M-62.341,600CDRECadre3.6812 of 5 stars$31.94-0.3%$37.50+17.4%-5.3%$1.30B$567.56M33.622,284TNDMTandem Diabetes Care4.2181 of 5 stars$18.64-1.6%$33.43+79.3%-57.1%$1.26B$940.20M-6.712,650Positive News Related Companies and Tools Related Companies LivaNova Competitors Warby Parker Competitors NovoCure Competitors LeMaitre Vascular Competitors National Vision Competitors Enovis Competitors CONMED Competitors Artivion Competitors Cadre Competitors Tandem Diabetes Care Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SIBN) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SiBone Please log in to your account or sign up in order to add this asset to your watchlist. Share SiBone With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
